Court revives more than 500 lawsuits over Fosamax femur fracture risk
By Brendan Pierson
Sept 20 (Reuters) -A U.S. appeals court on Friday revived more than 500 lawsuits alleging that Merck & Co MRK.N failed to warn that its osteoporosis drug Fosamax increased the risk of thigh bone fractures.
A unanimous panel of the Philadelphia-based 3rd U.S. Circuit Court of Appeals ruled that federal law did not block the plaintiffs' state law claims over the drug. Fosamax was acquired in 2021 by Organon OGN.N, which agreed to indemnify Merck against liability from the lawsuits.
"We're pleased by the Third Circuit's very careful and nuanced judgment, which gives Fosamax victims an opportunity to seek justice from Merck," David Frederick of Kellogg Hansen Todd Figel & Frederick, a lawyer for the plaintiffs, said in an email.
Merck referred a request for comment to Organon, which said it "remains confident in the efficacy and safety profile of Fosamax."
About 3,115 lawsuits over Fosamax were pending against Merck in both federal and state courts around the country as of June 30, according to Organon's most recent quarterly report. The cases affected by Friday's ruling are federal cases that have been centralized in New Jersey.
The federal litigation stretches back to 2008, and has now been dismissed and revived twice. All of those decisions have hinged on the issue of federal preemption - whether the federal law governing what pharmaceutical companies are required to put on drug labels overrides, or preempts, state law claims that the label fails to warn consumers.
Merck has argued that it does, saying that in 2009 it proposed adding a warning about femur fractures but was initially rejected by the FDA. The warning was eventually added in 2011.
Now-deceased U.S. District Judge Joel Pisano in Trenton, New Jersey, ruled in Merck's favor on the preemption issue in 2013, but the 3rd Circuit overturned that ruling in 2017, concluding that issue should have been decided by a jury.
The U.S. Supreme Court in 2019 ordered the issue reconsidered once again, saying it was a legal issue for a judge, not a jury.
In 2022, U.S. District Judge Freda Wolfson, who had taken over the case, again sided with Merck on preemption.
The 3rd Circuit on Friday, however, again reversed. It said that, even though the FDA had not approved the specific warning proposed by Merck in 2009, it would not necessarily have rejected any warning about femur fractures.
It said that Wolfson's decision failed to interpret the FDA's action "in a manner that disfavors pre-emption and carries out Congress's intent to permit displacement of state law only when it is abundantly clear that it is impossible for a manufacturer to comply with both federal and state law."
Circuit Judge Kent Jordan wrote the opinion, joined by Circuit Judges Peter Phipps and Arianna Freeman.
Wolfson has since retired, and the case is now assigned in the trial court to U.S. District Judge Karen Williams. The litigation will return to that court for potential future trials.
The case is In re Fosamax (alendronate sodium) Products Liability Litigation, 3rd U.S. Circuit Court of Appeals, No. 22-3412.
For plaintiffs: David Frederick of Kellogg Hansen Todd Figel & Frederick
For Merck: Yaakov Roth of Jones Day
Read more:
Merck defeats 500 lawsuits over Fosamax bone-fracture risk warnings
Supreme Court gives Merck another shot to avoid Fosamax lawsuits
(Reporting By Brendan Pierson in New York)
</body></html>
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
